These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37689301)

  • 1. Doxorubicin-loaded Niosomes functionalized with gelatine and alginate as pH-responsive drug delivery system: A 3D printing approach.
    Zaer M; Moeinzadeh A; Abolhassani H; Rostami N; Tavakkoli Yaraki M; Seyedi SA; Nabipoorashrafi SA; Bashiri Z; Moeinabadi-Bidgoli K; Moradbeygi F; Farmani AR; Hossein-Khannazer N
    Int J Biol Macromol; 2023 Dec; 253(Pt 2):126808. PubMed ID: 37689301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D-printing-assisted synthesis of paclitaxel-loaded niosomes functionalized by cross-linked gelatin/alginate composite: Large-scale synthesis and in-vitro anti-cancer evaluation.
    Hosseini F; Mirzaei Chegeni M; Bidaki A; Zaer M; Abolhassani H; Seyedi SA; Nabipoorashrafi SA; Ashrafnia Menarbazari A; Moeinzadeh A; Farmani AR; Tavakkoli Yaraki M
    Int J Biol Macromol; 2023 Jul; 242(Pt 1):124697. PubMed ID: 37156313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and physicochemical properties of cisplatin and doxorubicin encapsulated by niosome alginate nanocarrier for cancer therapy.
    Safari Sharafshadeh M; Tafvizi F; Khodarahmi P; Ehtesham S
    Int J Biol Macromol; 2023 Apr; 235():123686. PubMed ID: 36801304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation, Optimization and In vitro Evaluation of Doxorubicin-loaded into Hyaluronic Acid Coated Niosomes Against Breast Cancer.
    Faddah H; Nsairat H; Shalan NM; El-Tanani M; Alqudah DA; Alshaer W
    Chem Biodivers; 2024 Feb; 21(2):e202301470. PubMed ID: 38161147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioresponsive gingerol-loaded alginate-coated niosomal nanoparticles for targeting intracellular bacteria and cancer cells.
    Pashizeh F; Mansouri A; Bazzazan S; Abdihaji M; Khaleghian M; Bazzazan S; Rezei N; Eskandari A; Mashayekhi F; Heydari M; Tavakkoli Yaraki M
    Int J Biol Macromol; 2024 Feb; 258(Pt 2):128957. PubMed ID: 38154726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Toxicity of Doxorubicin Encapsulated into pH-Responsive Poly(β-Amino Ester)-Functionalized MCM-41 Silica Nanoparticles.
    Ávila-Ortega A; Carrillo-Cocom LM; Olán-Noverola CE; Nic-Can GI; Vilchis-Nestor AR; Talavera-Pech WA
    Curr Drug Deliv; 2020; 17(9):799-805. PubMed ID: 32723272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and Evaluation of Bone-Derived Nanoparticles as a Novel pH-Responsive Carrier for Delivery of Doxorubicin into Breast Cancer Cells.
    Haque ST; Islam RA; Gan SH; Chowdhury EH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937817
    [No Abstract]   [Full Text] [Related]  

  • 8. Modified methods of nanoparticles synthesis in pH-sensitive nano-carriers production for doxorubicin delivery on MCF-7 breast cancer cell line.
    Hamidu A; Mokrish A; Mansor R; Razak ISA; Danmaigoro A; Jaji AZ; Bakar ZA
    Int J Nanomedicine; 2019; 14():3615-3627. PubMed ID: 31190815
    [No Abstract]   [Full Text] [Related]  

  • 9. Chitosan Immobilization on Bio-MOF Nanostructures: A Biocompatible pH-Responsive Nanocarrier for Doxorubicin Release on MCF-7 Cell Lines of Human Breast Cancer.
    Abazari R; Mahjoub AR; Ataei F; Morsali A; Carpenter-Warren CL; Mehdizadeh K; Slawin AMZ
    Inorg Chem; 2018 Nov; 57(21):13364-13379. PubMed ID: 30351060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
    Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
    Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
    [No Abstract]   [Full Text] [Related]  

  • 12. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decapeptide functionalized targeted mesoporous silica nanoparticles with doxorubicin exhibit enhanced apoptotic effect in breast and prostate cancer cells.
    Tambe P; Kumar P; Paknikar KM; Gajbhiye V
    Int J Nanomedicine; 2018; 13():7669-7680. PubMed ID: 30538451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facile preparation of a pH-sensitive biocompatible nanocarrier based on magnetic layered double hydroxides/Cu MOFs-chitosan crosslinked к-carrageenan for controlled doxorubicin delivery to breast cancer cells.
    Taghikhani A; Babazadeh M; Davaran S; Ghasemi E
    Colloids Surf B Biointerfaces; 2024 Nov; 243():114122. PubMed ID: 39079184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Chemical Binding of Doxorubicin Hydrochloride to Gold Nanoparticles, Versus Electrostatic Adsorption, on the In Vitro Drug Release and Cytotoxicity to Breast Cancer Cells.
    Zayed GM; Kamal I; Abdelhafez WA; M Alsharif F; Amin MA; Shaykoon MSA; Sarhan HA; Abdelsalam AM
    Pharm Res; 2018 Mar; 35(6):112. PubMed ID: 29603025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key Magnetized Exosomes for Effective Targeted Delivery of Doxorubicin Against Breast Cancer Cell Types in Mice Model.
    Xu W; Wang K; Wang K; Zhao Y; Yang Z; Li X
    Int J Nanomedicine; 2024; 19():10711-10724. PubMed ID: 39464677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
    Ling L; Ismail M; Du Y; Yao C; Li X
    Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pH-Responsive PEGylated Niosomal Nanoparticles as an Active-Targeting Cyclophosphamide Delivery System for Gastric Cancer Therapy.
    Khodabakhsh F; Bourbour M; Yaraki MT; Bazzazan S; Bakhshandeh H; Ahangari Cohan R; Tan YN
    Molecules; 2022 Aug; 27(17):. PubMed ID: 36080186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new formulation of hydrophobin-coated niosome as a drug carrier to cancer cells.
    Barani M; Mirzaei M; Torkzadeh-Mahani M; Lohrasbi-Nejad A; Nematollahi MH
    Mater Sci Eng C Mater Biol Appl; 2020 Aug; 113():110975. PubMed ID: 32487392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
    Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
    Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.